Literature DB >> 18848941

A mouse model of Clostridium difficile-associated disease.

Xinhua Chen1, Kianoosh Katchar, Jeffrey D Goldsmith, Nanda Nanthakumar, Adam Cheknis, Dale N Gerding, Ciarán P Kelly.   

Abstract

BACKGROUND & AIMS: Infection with Clostridium difficile causes nosocomial antibiotic-associated diarrhea and colitis. Hamsters historically have been used to investigate disease pathogenesis and treatment, but are not ideal models because of the lack of hamster-specific reagents and genetically modified animals, and because they develop fulminant disease. The aim of this study was to establish a mouse model of antibiotic-induced C. difficile-associated disease (CDAD) that more closely resembles human disease.
METHODS: C57BL/6 mice were exposed to a mixture of antibiotics (kanamycin, gentamicin, colistin, metronidazole, and vancomycin) for 3 days. Two days later, they were given injections of clindamycin and then challenged 1 day later with different doses of C. difficile.
RESULTS: Mice that were exposed to antibiotics and then challenged with C. difficile developed diarrhea and lost weight. Disease severity varied from fulminant to minimal in accordance with the challenge dose. Typical histologic features of CDAD were evident. Oral vancomycin prevented CDAD in all mice, but 68% died from colitis after treatment was discontinued. All animals that survived an initial episode of CDAD showed no evidence of diarrhea or colitis after subsequent rechallenge with C. difficile. Different strains of C. difficile tested in the model showed different levels of virulence in mice.
CONCLUSIONS: We have developed a mouse model of CDAD that closely represents the human disease. In light of the recent substantial increases in CDAD incidence and severity, this model will be valuable in testing new treatments, examining disease pathogenesis, and elucidating mechanisms of protective immunity.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18848941     DOI: 10.1053/j.gastro.2008.09.002

Source DB:  PubMed          Journal:  Gastroenterology        ISSN: 0016-5085            Impact factor:   22.682


  249 in total

1.  Clostridium difficile toxins induce VEGF-A and vascular permeability to promote disease pathogenesis.

Authors:  Jun Huang; Ciarán P Kelly; Kyriaki Bakirtzi; Javier A Villafuerte Gálvez; Dena Lyras; Steven J Mileto; Sarah Larcombe; Hua Xu; Xiaotong Yang; Kelsey S Shields; Weishu Zhu; Yi Zhang; Jeffrey D Goldsmith; Ishan J Patel; Joshua Hansen; Meijin Huang; Seppo Yla-Herttuala; Alan C Moss; Daniel Paredes-Sabja; Charalabos Pothoulakis; Yatrik M Shah; Jianping Wang; Xinhua Chen
Journal:  Nat Microbiol       Date:  2018-12-03       Impact factor: 17.745

2.  Interleukin-22 regulates the complement system to promote resistance against pathobionts after pathogen-induced intestinal damage.

Authors:  Mizuho Hasegawa; Shoko Yada; Meng Zhen Liu; Nobuhiko Kamada; Raúl Muñoz-Planillo; Nhu Do; Gabriel Núñez; Naohiro Inohara
Journal:  Immunity       Date:  2014-10-16       Impact factor: 31.745

3.  The role of Gr-1(+) cells and tumour necrosis factor-α signalling during Clostridium difficile colitis in mice.

Authors:  Andrew J McDermott; Kathryn E Higdon; Ryan Muraglia; John R Erb-Downward; Nicole R Falkowski; Roderick A McDonald; Vincent B Young; Gary B Huffnagle
Journal:  Immunology       Date:  2015-04       Impact factor: 7.397

4.  Systemic dissemination of Clostridium difficile toxins A and B is associated with severe, fatal disease in animal models.

Authors:  Jennifer Steele; Kevin Chen; Xingmin Sun; Yongrong Zhang; Haiying Wang; Saul Tzipori; Hanping Feng
Journal:  J Infect Dis       Date:  2011-12-05       Impact factor: 5.226

5.  Clostridium difficile infection aggravates colitis in interleukin 10-deficient mice.

Authors:  Mi Na Kim; Seong-Joon Koh; Jung Mogg Kim; Jong Pil Im; Hyun Chae Jung; Joo Sung Kim
Journal:  World J Gastroenterol       Date:  2014-12-07       Impact factor: 5.742

6.  Zinc deficiency alters host response and pathogen virulence in a mouse model of enteroaggregative Escherichia coli-induced diarrhea.

Authors:  David T Bolick; Glynis L Kolling; John H Moore; Luís Antônio de Oliveira; Kenneth Tung; Casandra Philipson; Monica Viladomiu; Raquel Hontecillas; Josep Bassaganya-Riera; Richard L Guerrant
Journal:  Gut Microbes       Date:  2014

Review 7.  Microbiota-mediated colonization resistance against intestinal pathogens.

Authors:  Charlie G Buffie; Eric G Pamer
Journal:  Nat Rev Immunol       Date:  2013-10-07       Impact factor: 53.106

Review 8.  Clostridium difficile colitis: pathogenesis and host defence.

Authors:  Michael C Abt; Peter T McKenney; Eric G Pamer
Journal:  Nat Rev Microbiol       Date:  2016-08-30       Impact factor: 60.633

9.  Disease Progression and Resolution in Rodent Models of Clostridium difficile Infection and Impact of Antitoxin Antibodies and Vancomycin.

Authors:  Peter Warn; Pia Thommes; Abdul Sattar; David Corbett; Amy Flattery; Zuo Zhang; Todd Black; Lorraine D Hernandez; Alex G Therien
Journal:  Antimicrob Agents Chemother       Date:  2016-10-21       Impact factor: 5.191

10.  Mechanisms of protection against Clostridium difficile infection by the monoclonal antitoxin antibodies actoxumab and bezlotoxumab.

Authors:  Zhiyong Yang; Jeremy Ramsey; Therwa Hamza; Yongrong Zhang; Shan Li; Harris G Yfantis; Dong Lee; Lorraine D Hernandez; Wolfgang Seghezzi; Jamie M Furneisen; Nicole M Davis; Alex G Therien; Hanping Feng
Journal:  Infect Immun       Date:  2014-12-08       Impact factor: 3.441

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.